AMIGO2

Summary

AMIGO2 (adhesion molecule with Ig like domain 2, HGNC:24073) is a protein-coding gene on chromosome 12q13.11, encoding Amphoterin-induced protein 2 (Q86SJ2). Required for depolarization-dependent survival of cultured cerebellar granule neurons.

Predicted to be involved in several processes, including heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules; homophilic cell adhesion via plasma membrane adhesion molecules; and positive regulation of synapse assembly. Predicted to be located in nucleus and plasma membrane. Predicted to be active in membrane. Biomarker of gastric adenocarcinoma.

Source: NCBI Gene 347902 — RefSeq curated summary.

At a glance

• Gene–disease (curated): craniofacial microsomia (Limited, GenCC)
• GWAS associations: 1
• Clinical variants (ClinVar): 74 total — 1 pathogenic
• MANE Select transcript: NM_001370299

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24073
Approved symbol	AMIGO2
Name	adhesion molecule with Ig like domain 2
Location	12q13.11
Locus type	gene with protein product
Status	Approved
Aliases	ALI1, DEGA
Ensembl gene	ENSG00000139211
Ensembl biotype	protein_coding
OMIM	615690
Entrez	347902

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 12 protein_coding

ENST00000266581, ENST00000429635, ENST00000550413, ENST00000872221, ENST00000872222, ENST00000872223, ENST00000872224, ENST00000872225, ENST00000872226, ENST00000962916, ENST00000962917, ENST00000962918

RefSeq mRNA: 3 — MANE Select: NM_001370299 NM_001143668, NM_001370299, NM_181847

CCDS: CCDS8751

Canonical transcript exons

ENST00000550413 — 3 exons

Exon	Start	End
ENSE00002354530	47079462	47079959
ENSE00002392496	47079142	47079248
ENSE00002413473	47076447	47079065

Expression profiles

Bgee: expression breadth ubiquitous, 271 present calls, max score 99.28.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 13.3244 / max 398.6528, expressed in 1302 samples.

FANTOM5 promoters (12 alternative TSS)

Promoter ID	TPM avg	Samples expressed
130651	7.0576	1085
130645	2.0803	839
130648	1.8040	650
130654	0.5374	310
130653	0.4863	280
130649	0.3284	199
130650	0.2575	144
130643	0.2204	108
130647	0.2101	126
130644	0.1200	79

Top tissues by expression

291 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
blood vessel layer	UBERON:0004797	99.28	gold quality
germinal epithelium of ovary	UBERON:0001304	98.53	gold quality
renal glomerulus	UBERON:0000074	97.79	gold quality
metanephric glomerulus	UBERON:0004736	97.43	gold quality
epithelium of mammary gland	UBERON:0003244	96.89	gold quality
mammary duct	UBERON:0001765	96.83	gold quality
stromal cell of endometrium	CL:0002255	96.00	gold quality
visceral pleura	UBERON:0002401	95.80	gold quality
popliteal artery	UBERON:0002250	95.41	gold quality
tibial artery	UBERON:0007610	95.39	gold quality
artery	UBERON:0001637	94.87	gold quality
palpebral conjunctiva	UBERON:0001812	93.88	gold quality
mammary gland	UBERON:0001911	93.77	gold quality
thoracic mammary gland	UBERON:0005200	93.71	gold quality
left uterine tube	UBERON:0001303	93.28	gold quality
saphenous vein	UBERON:0007318	93.19	gold quality
aorta	UBERON:0000947	92.96	gold quality
adrenal tissue	UBERON:0018303	92.89	gold quality
caput epididymis	UBERON:0004358	92.58	gold quality
pleura	UBERON:0000977	92.00	gold quality
smooth muscle tissue	UBERON:0001135	91.62	gold quality
left coronary artery	UBERON:0001626	91.60	gold quality
cranial nerve II	UBERON:0000941	91.53	gold quality
hair follicle	UBERON:0002073	91.41	gold quality
coronary artery	UBERON:0001621	91.32	gold quality
right coronary artery	UBERON:0001625	91.26	gold quality
metanephros	UBERON:0000081	91.20	gold quality
endothelial cell	CL:0000115	91.05	gold quality
seminal vesicle	UBERON:0000998	91.01	gold quality
superior vestibular nucleus	UBERON:0007227	90.80	gold quality

Single-cell (SCXA)

Detected in 7 experiment(s), a significant marker in 6.

Experiment	Marker?	Max mean expression
E-CURD-7	yes	413.00
E-ENAD-21	yes	409.50
E-ANND-3	yes	10.48
E-MTAB-5061	yes	9.62
E-GEOD-81608	yes	5.42
E-ENAD-27	yes	4.37
E-MTAB-8060	no	491.46

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): RELA

miRNA regulators (miRDB)

90 targeting AMIGO2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3646	100.00	73.56	5283
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-485-3P	99.98	70.68	1585
HSA-MIR-539-3P	99.98	70.74	1616
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-LET-7C-3P	99.95	73.42	2862
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-106A-5P	99.90	73.94	2683
HSA-MIR-17-5P	99.89	73.83	2665
HSA-MIR-20B-5P	99.88	74.01	2621
HSA-MIR-519D-3P	99.88	73.97	2607
HSA-MIR-526B-3P	99.88	74.06	2587
HSA-MIR-93-5P	99.88	73.98	2606
HSA-MIR-106B-5P	99.88	74.72	2795
HSA-MIR-20A-5P	99.88	74.76	2769
HSA-MIR-7845-5P	99.88	64.88	771
HSA-MIR-4307	99.82	70.45	3374
HSA-MIR-6515-3P	99.82	68.19	1933
HSA-MIR-489-3P	99.80	66.46	839
HSA-MIR-4760-5P	99.80	69.88	1619
HSA-MIR-4658	99.77	64.94	514
HSA-MIR-4319	99.76	69.83	2586
HSA-MIR-4517	99.76	69.19	1867

Literature-anchored findings (GeneRIF, showing 13)

• Expression of ali1 promotes depolarization-dependent survival of cerebellar granule neurons. Mouse ali1 mapped to a chromosome 15 locus syntenic to candidate loci for familial Alzheimer’s disease type 5 and Parkinson’s disease 8 on human chromosome 12. (PMID:12843293)
• Stable expression of a DEGA/AMIGO-2 antisense construct led to altered morphology, increased ploidy, chromosomal instability, decreased cell adhesion/migration, and a nearly complete abrogation of tumorigenicity in nude mice. (PMID:15107827)
• AMIGO2 is an important regulator of the PDK1-Akt pathway. (PMID:26553931)
• Amigo2, which is a member of the Amigo family that shows high species conservation, may be involved in determining liver metastasis by preferential adhesion of the tumour cells to liver endothelial cells. (PMID:28272394)
• this study uncovers mechanisms underlying the therapeutic effects of BETi in melanoma and reveals the AMIGO2-PTK7 axis as a targetable pathway for metastatic melanoma. (PMID:29149598)
• AMIGO2 Expression as a Potential Prognostic Biomarker for Gastric Cancer. (PMID:33288564)
• In vivo selection of highly metastatic human ovarian cancer sublines reveals role for AMIGO2 in intra-peritoneal metastatic regulation. (PMID:33524500)
• AMIGO2 contained in cancer cell-derived extracellular vesicles enhances the adhesion of liver endothelial cells to cancer cells. (PMID:35039535)
• The impact of AMIGO2 on prognosis and hepatic metastasis in gastric cancer patients. (PMID:35296279)
• Liver Metastasis Formation Is Defined by AMIGO2 Expression via Adhesion to Hepatic Endothelial Cells in Human Gastric and Colorectal Cancer Cells. (PMID:35843033)
• AMIGO2 attenuates innate cisplatin sensitivity by suppression of GSDME-conferred pyroptosis in non-small cell lung cancer. (PMID:37438979)
• AMIGO2 is a pivotal therapeutic target related to M2 polarization of macrophages in pancreatic ductal adenocarcinoma. (PMID:38189855)
• AMIGO2 is involved in the spread of peritoneal metastasis in serous ovarian cancer via promoting adhesion to the peritoneal mesothelial cells. (PMID:38811439)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Amigo2	ENSMUSG00000048218
rattus_norvegicus	Amigo2	ENSRNOG00000007032

Paralogs (2): AMIGO3 (ENSG00000176020), AMIGO1 (ENSG00000181754)

Protein

Protein identifiers

Amphoterin-induced protein 2 — Q86SJ2 (reviewed: Q86SJ2)

Alternative names: AMIGO-2, Alivin-1, Differentially expressed in gastric adenocarcinomas

All UniProt accessions (1): Q86SJ2

UniProt curated annotations — full annotation on UniProt →

Function. Required for depolarization-dependent survival of cultured cerebellar granule neurons. May mediate homophilic as well as heterophilic cell-cell interaction with AMIGO1 or AMIGO3. May contribute to signal transduction through its intracellular domain. May be required for tumorigenesis of a subset of gastric adenocarcinomas.

Subunit / interactions. Binds itself as well as AMIGO1 and AMIGO3.

Subcellular location. Cell membrane. Nucleus.

Tissue specificity. Highest levels in breast, ovary, cervix, and uterus. Lower levels in lung, colon, and rectum. Differentially expressed in 56% of thyroid, 57% of pancreatic and 45% of stomach cancers.

Similarity. Belongs to the immunoglobulin superfamily. AMIGO family.

RefSeq proteins (3): NP_001137140, NP_001357228, NP_862830 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000483	Cys-rich_flank_reg_C	Domain
IPR001611	Leu-rich_rpt	Repeat
IPR003591	Leu-rich_rpt_typical-subtyp	Repeat
IPR003599	Ig_sub	Domain
IPR007110	Ig-like_dom	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR031283	AMIGO	Family
IPR032675	LRR_dom_sf	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily

Pfam: PF13855, PF13927

UniProt features (28 total): glycosylation site 8, repeat 6, disulfide bond 5, domain 3, topological domain 2, signal peptide 1, chain 1, region of interest 1, transmembrane region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q86SJ2-F1	75.93	0.43

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (5): 41–47, 45–54, 232–260, 234–282, 310–363

Glycosylation sites (8): 58, 104, 281, 288, 345, 373, 381, 384

Function

Pathways and Gene Ontology

Reactome pathways

6 pathways

ID	Pathway
R-HSA-9013149	RAC1 GTPase cycle
R-HSA-9013423	RAC3 GTPase cycle
R-HSA-162582	Signal Transduction
R-HSA-194315	Signaling by Rho GTPases
R-HSA-9012999	RHO GTPase cycle
R-HSA-9716542	Signaling by Rho GTPases, Miro GTPases and RHOBTB3

MSigDB gene sets: 227 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_TUMORAL_MACROPHAGE_UP, LI_CISPLATIN_RESISTANCE_DN, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, GOBP_HETEROPHILIC_CELL_CELL_ADHESION, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, GOBP_SYNAPSE_ASSEMBLY, FISCHER_G1_S_CELL_CYCLE, BOYAULT_LIVER_CANCER_SUBCLASS_G2, GOBP_POSITIVE_REGULATION_OF_SYNAPSE_ASSEMBLY, GOBP_REGULATION_OF_CELL_JUNCTION_ASSEMBLY, GOBP_REGULATION_OF_NERVOUS_SYSTEM_DEVELOPMENT, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, GOBP_POSITIVE_REGULATION_OF_NERVOUS_SYSTEM_DEVELOPMENT, TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_SUSTAINDED_IN_ERYTHROCYTE_UP, GOBP_CELL_CELL_ADHESION

GO Biological Process (6): homophilic cell-cell adhesion (GO:0007156), heterophilic cell-cell adhesion (GO:0007157), brain development (GO:0007420), negative regulation of programmed cell death (GO:0043069), positive regulation of synapse assembly (GO:0051965), cell adhesion (GO:0007155)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (3): nucleus (GO:0005634), plasma membrane (GO:0005886), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-4 pathways:

Category	Pathways
RHO GTPase cycle	2
Signaling by Rho GTPases, Miro GTPases and RHOBTB3	1
Signaling by Rho GTPases	1
Signal Transduction	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cell-cell adhesion	2
central nervous system development	1
animal organ development	1
head development	1
programmed cell death	1
regulation of programmed cell death	1
negative regulation of cellular process	1
synapse assembly	1
positive regulation of nervous system development	1
regulation of synapse assembly	1
positive regulation of cell junction assembly	1
cellular process	1
binding	1
intracellular membrane-bounded organelle	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1108 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
AMIGO2	B3GNT5	Q9BYG0	588
AMIGO2	RGS14	O43566	546
AMIGO2	SERPING1	P05155	546
AMIGO2	PCP4	P48539	494
AMIGO2	EMP1	P54849	479
AMIGO2	TM4SF1	P30408	447
AMIGO2	CLDN2	P57739	396
AMIGO2	RND3	P52199	388
AMIGO2	TSHZ1	Q6ZSZ6	385
AMIGO2	SLC10A6	Q3KNW5	383
AMIGO2	FKBP5	Q13451	360
AMIGO2	SRGN	P10124	355
AMIGO2	FBLN5	Q9UBX5	354
AMIGO2	CD109	Q6YHK3	340
AMIGO2	NECAB2	Q7Z6G3	319

IntAct

13 interactions, top by confidence:

A	B	Type	Score
TMED8	AMIGO2	psi-mi:“MI:0915”(physical association)	0.560
CNPY3	LRIG2	psi-mi:“MI:0914”(association)	0.530
LDLRAD1	ADAM10	psi-mi:“MI:0914”(association)	0.530
AMIGO2	CACNA1A	psi-mi:“MI:0915”(physical association)	0.510
CACNA1A	AMIGO2	psi-mi:“MI:0915”(physical association)	0.510
	SHTN1	psi-mi:“MI:0914”(association)	0.350
	TMEM223	psi-mi:“MI:0914”(association)	0.350
	TNFRSF10A	psi-mi:“MI:0914”(association)	0.350
CLGN	TMEM131L	psi-mi:“MI:0914”(association)	0.350
LAMP1	PIPSL	psi-mi:“MI:2364”(proximity)	0.270
TMED8	AMIGO2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (62): AMIGO2 (Co-fractionation), AMIGO2 (Affinity Capture-MS), AMIGO2 (Proximity Label-MS), AMIGO2 (Proximity Label-MS), AMIGO2 (Affinity Capture-Western), AMIGO1 (Affinity Capture-Western), AMIGO2 (Affinity Capture-Western), AMIGO3 (Affinity Capture-Western), AMIGO2 (Affinity Capture-Western), AMIGO2 (Proximity Label-MS), AMIGO2 (Two-hybrid), AMIGO2 (Affinity Capture-MS), AMIGO2 (Affinity Capture-MS), AMIGO2 (Affinity Capture-MS), AMIGO2 (Proximity Label-MS)

ESM2 similar proteins: A1A4H9, A2ARI4, A6NDA9, B0BLW3, B4F7C5, D3ZAL8, D3ZTV3, D4A6D8, D4A7P2, E7FE13, F1MT22, O14498, O43155, O43300, P0DM44, P83286, Q149C3, Q5NVQ6, Q5R6B1, Q5R7M3, Q5RAC4, Q6PFC5, Q6RKD8, Q80WD0, Q80XG9, Q80ZD7, Q80ZD8, Q80ZD9, Q810C0, Q810C1, Q86SJ2, Q86UE6, Q86UN2, Q86VH4, Q86VH5, Q86WK6, Q8BGA3, Q8BLU0, Q8BZ81, Q8C2S7

Diamond homologs: O88280, Q5R7M3, Q6WRI0, Q7TNJ4, Q80ZD5, Q80ZD7, Q80ZD8, Q80ZD9, Q86SJ2, Q86WK6, Q86WK7, Q8C2S7, Q96JA1, Q13308, Q4R8Y9, Q8BKG3, O75093, O75094, O88279, O94813, Q3URE9, Q6P3Y9, Q80TR4, Q9R1B9, Q9WVC1, G5EFX6, P21793, Q6P1C6, Q6UXM1, Q9TTE2, Q9WVB4, Q9XSD9, P70193, A6H789, E5DHB5, Q8VCH9, Q96PB8, O02678, O46390, O46403

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

74 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	64
Likely benign	2
Benign	1

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1710515	GRCh37/hg19 12q12-13.11(chr12:44661149-48921204)x1	Pathogenic

SpliceAI

381 predictions. Top by Δscore:

Variant	Effect	Δscore
12:47079460:A:AC	donor_gain	1.0000
12:47079461:C:CC	donor_gain	1.0000
12:47079461:CGGTG:C	donor_gain	1.0000
12:47079432:TAGCA:T	donor_gain	0.9900
12:47079433:AGCAA:A	donor_gain	0.9900
12:47079461:CG:C	donor_gain	0.9900
12:47079434:G:C	donor_gain	0.9800
12:47079455:AACTC:A	donor_loss	0.9800
12:47079457:CTCA:C	donor_loss	0.9800
12:47079460:A:T	donor_loss	0.9800
12:47079461:C:A	donor_loss	0.9800
12:47079511:T:TA	donor_gain	0.9800
12:47079721:TGAAG:T	donor_loss	0.9800
12:47079723:AAGG:A	donor_loss	0.9800
12:47079724:AGG:A	donor_loss	0.9800
12:47079725:GG:G	donor_loss	0.9800
12:47079726:G:A	donor_loss	0.9800
12:47079727:T:G	donor_loss	0.9800
12:47080713:A:G	donor_gain	0.9800
12:47079062:GAACC:G	acceptor_loss	0.9700
12:47079067:T:G	acceptor_loss	0.9700
12:47079454:AAACT:A	donor_loss	0.9700
12:47079461:CGGT:C	donor_gain	0.9700
12:47080717:GA:G	donor_gain	0.9700
12:47079453:AAAAC:A	donor_loss	0.9600
12:47079461:CGG:C	donor_gain	0.9600
12:47079566:T:TA	donor_gain	0.9600
12:47079723:A:T	donor_gain	0.9600
12:47080712:GA:G	donor_gain	0.9600
12:47079504:AGTG:A	donor_gain	0.9500

AlphaMissense

3437 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:47077776:A:C	S409R	0.999
12:47077776:A:T	S409R	0.999
12:47077778:T:G	S409R	0.999
12:47077922:A:C	Y361D	0.998
12:47077960:A:G	L348P	0.998
12:47078034:C:A	W323C	0.998
12:47078034:C:G	W323C	0.998
12:47078036:A:G	W323R	0.998
12:47078036:A:T	W323R	0.998
12:47077787:A:G	C406R	0.997
12:47077914:A:C	C363W	0.997
12:47078478:A:C	N175K	0.997
12:47078478:A:T	N175K	0.997
12:47078494:A:G	L170P	0.997
12:47078566:A:G	L146P	0.997
12:47078550:A:C	N151K	0.996
12:47078550:A:T	N151K	0.996
12:47078566:A:T	L146H	0.996
12:47078638:A:G	L122P	0.996
12:47078638:A:T	L122H	0.996
12:47078769:G:C	N78K	0.996
12:47078769:G:T	N78K	0.996
12:47078779:A:G	L75P	0.996
12:47078843:A:G	C54R	0.996
12:47077789:G:T	A405D	0.995
12:47077915:C:T	C363Y	0.995
12:47077916:A:G	C363R	0.995
12:47078560:A:G	L148P	0.995
12:47078560:A:T	L148H	0.995
12:47078622:A:C	N127K	0.995

dbSNP variants (sampled 300 via entrez): RS1000071932 (12:47079799 G>A,T), RS1000339042 (12:47081253 T>A), RS1000368638 (12:47081006 T>C), RS1001005665 (12:47078549 G>T), RS1001479528 (12:47077895 G>A,T), RS1001671024 (12:47079798 A>G), RS1001683313 (12:47080972 G>A,C), RS1002114376 (12:47080899 T>C), RS1002414024 (12:47077368 G>A,C), RS1003195055 (12:47076065 G>C), RS1003228338 (12:47075766 G>A), RS1003827913 (12:47075925 C>A), RS1003923611 (12:47079351 G>A), RS1004827093 (12:47078330 G>A,C,T), RS1005359627 (12:47076374 T>C)

Disease associations

OMIM: gene MIM:615690 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
craniofacial microsomia	Limited	Autosomal dominant

Mondo (1): craniofacial microsomia (MONDO:0015397)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST006585_2494	Blood protein levels	7.000000e-07

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D006053	Goldenhar Syndrome	C05.116.099.370.231.576.410; C05.660.207.231.576.410; C16.131.621.207.231.576.410

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

81 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression	7
sodium arsenite	decreases expression, affects cotreatment, increases abundance, increases expression	5
Estradiol	affects cotreatment, decreases expression, increases expression	5
trichostatin A	affects cotreatment, increases expression	3
Air Pollutants	increases abundance, increases expression, decreases expression	3
Tetrachlorodibenzodioxin	affects cotreatment, decreases expression, affects expression	3
Particulate Matter	increases abundance, increases expression, decreases expression	3
ochratoxin A	affects expression, decreases acetylation, decreases expression	2
mercuric bromide	increases expression, affects cotreatment	2
monomethylarsonous acid	decreases expression, increases expression	2
(+)-JQ1 compound	decreases expression	2
Panobinostat	affects cotreatment, increases expression	2
Acetaminophen	decreases expression	2
Indomethacin	affects cotreatment, decreases expression, increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Cyclosporine	decreases expression, increases expression	2
Asbestos, Serpentine	affects expression, decreases methylation	2
Asbestos, Crocidolite	affects expression	2
Cadmium Chloride	decreases expression, increases abundance, increases expression	2
aristolochic acid I	decreases expression	1
TL8-506	affects cotreatment, increases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	decreases expression	1
deoxynivalenol	decreases expression	1
lead acetate	increases expression	1
beta-lapachone	decreases expression	1
mono-(2-ethylhexyl)phthalate	increases expression	1
butyraldehyde	decreases expression	1
potassium bromate	decreases expression	1

Clinical trials (associated diseases)

10 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT01674439	PHASE2	COMPLETED	Clinical Trial of Fat Grafts Supplemented With Adipose-derived Regenerative Cells
NCT05610878	PHASE1	RECRUITING	Efficacy of Preconditioned Adipose-Derived Stem Cells in Fat Grafting
NCT02224677	Not specified	COMPLETED	Craniofacial Microsomia: Longitudinal Outcomes in Children Pre-Kindergarten (CLOCK)
NCT02494752	Not specified	UNKNOWN	Role of Mesenchymal Stem Cells in Fat Grafting
NCT03806361	Not specified	COMPLETED	Fat Grafts With Adipose-derived Regenerative Cells for Soft Tissue Reconstruction in Children
NCT03861650	Not specified	COMPLETED	Evaluation of Effect of Bone Marrow Aspirate Concentrate on Distracted Mandibular Bone Properties
NCT03869021	Not specified	COMPLETED	Computer Guided for Mandibular Distraction Osteogenesis
NCT04056858	Not specified	COMPLETED	Study of a Candidate Gene Involved in Goldenhar Syndrome.
NCT04351893	Not specified	COMPLETED	Craniofacial Microsomia: Accelerating Understanding of the Significance and Etiology
NCT04931056	Not specified	COMPLETED	A Post Market Clinical Follow-up Study on Biomet Microfixation HTR PEKK (Midface), Facial & Mandibular Plates.